Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Eli Lilly's first-quarter results were driven by exceptional sales of its diabetes treatment, Mounjaro, and weight loss drug, Zepbound. Mounjaro achieved $3.84 billion in revenue, a remarkable 113% ...

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at ...

Eli Lilly and Creyon Bio have entered into a partnership worth over $1bn to develop RNA-targeted oligonucleotide (oligo) ...

Perhaps most high profile was its $2.5 billion deal to buy the lead cancer program from Scorpion Therapeutics Inc. Lilly also recently signed a collaboration and license agreement with Cambridge ...

Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to ...